Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Ishihara J, et al:Sci Transl Med, 9:eaan0401, 2017
石原 純,石原亜香,Jeffrey A. Hubbell
Jun Ishihara1)2)/Ako Ishihara1)/Jeffrey A. Hubbell1)2):Institute for Molecular Engineering, University of Chicago1)/Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne2)(シカゴ大学分子工学研究科1)/スイス連邦工科大学ローザンヌ校2))